Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Genomic profiling of penile squamous cell carcinoma reveals major biomarkers...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Pembrolizumab shows notable antitumour activity for patients with high-risk...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC ( Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )

More from ecancer